The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children

Respiratory Medicine

Volumn 93, Issue 6, 1999, Pages 402-407

  Barnes, N C ^a   Thwaites, R M A ^b   Price, M J ^b  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE;

ADULT; ARTICLE; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; DATA BASE; DRUG SAFETY; DRUG SENSITIVITY; HEALTH CARE COST; HUMAN; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; METERED DOSE INHALER; OUTCOMES RESEARCH; PEAK EXPIRATORY FLOW; PEDIATRICS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYMPTOM;

EID: 0032993104     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.1999.0577     Document Type: Article

References (28)

1. National Institutes of Health/National Heart, Lung and Blood Institute. Global strategy for asthma management and prevention. Washington, DC: NHLBI/ WHO workshop report, publication number 95-3659, January 1995.
2. Weiss KB. An overview of recent trends in asthma epidemiology. Eur Respir Rev 1996; 35: 101-104.
3. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma. Can it be reduced? Pharmacoeconomics 1993; 3: 205-219.
4. The British Guidelines on asthma management. Thorax 1997; 52 (Suppl. 1): S1-S21.
5. National Heart, Lung and Blood Institute. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992; 5: 601-641.
6. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 (Suppl. A): 22-28.
7. Barnes NC, Marone G, Di Maria GH et al., on behalf of an International Study Group. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. Eur Respir J 1993; 6: 877-885.
8. Gustafsson P, Tsanakas J, Gold M et al. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone dipropionate 400 μg/day in mild and moderate asthma. Arch Dis Child 1993; 69: 206-211.
9. Barnes NC, Hallett C, Harris TAJ. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998; 92: 95-104.
10. Steinmetz KO, Trautmann M, Volmer T. Cost-effectiveness of fluticasone propionate (500 μg daily) via MDI and budesonide (1200 μg daily) via Turbohaler in the treatment of steroid-naïve patients with moderate asthma. Eur Respir J 1997; 10 (Suppl. 25) 227S.
11. Booth PC, Capsey LJ, Langdon CG et al. A comparison of the cost-effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br J Med Econ 1995; 8: 65-72.
12. Rutten van Molken M, van Doorslaer D, Buxton M, Till D. International cost-effectiveness study comparing formoterol and salmeterol. J Allergy Clin Immunol 1998; 101: S69.
13. Rutten van Molken MPMH, Van Doorslaer EKA, Jansen MCC et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975-982.
14. Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness. An illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics 1993; 4: 345-352.
15. Langdon CG, Capsey LJ on behalf of a U.K. study group. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhaler devices. Br J Clin Res 1994; 5: 85-89.
16. Langdon CG, Thompson J, on behalf of a U.K. study group. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered dose inhalers in adults with mild-to-moderate asthma. Br J Clin Res 1994; 5: 73-84.
17. Connolly A, on behalf of a U.K. study group. A comparison of fluticasone propionate 100 μg twice daily with 200 μg budesonide twice daily via their respective powder devices in the treatment of mild asthma. Eur J Clin Res 1995; 7: 15-29.
18. Backman R, Pickering CA, Baumgarten C et al. Fluticasone propionate Diskus 250 μg bd compared with budesonide Turbohaler 600 μg bd in adult asthmatics. J Allergy Clin Immunol 1996; 96: A267.
19. Williams J, Richards KA, on behalf of a U.K. Study Group. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the budesonide Turbohaler inhaler in paediatric patients. Br J Clin Pract 1997; 51: -153.
20. Ringdal N, Swinburn P, Backman R et al. A blinded comparison of fluticasone propionate with budesonide in adult patients with moderate-to-severe asthma. Mediators Inflamm 1996; 5: 382-389.
21. Steinmetz KO, Trautmann M. Efficacy of fluticasone propionate (0·5 mg daily) via MDI and budesonide (1·2mg daily) via Turbohaler in the treatment of steroid-naive asthmatics. Am J Respir Crit Care Med 1996; 153: A338.
22. Compendium of Health Statistics. 9th ed. London: Office of Health Economics, 1995.
23. Rutten van Molken MPMH, Van Doorslaer EKA, Jansen MCC et al. Cost effectiveness of inhaled corticosteroids plus bronchodilator monotherapy in children with asthma. Pharmacoeconomics 1993; 4: 257-270.
24. Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. Respir Med 1998; 92: 351-353.
25. Connett GJ, Lenney W, McConchie SM. The cost-effectiveness of budesonide in severe asthmatics aged one to three years. Am J Respir Crit Care Med 1995; 151: 975-982.
26. O'Byrne P, Cuddy L, Taylor DW et al. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J 1996; 3: 169-175.
27. Steinmetz K, Volmer T, Trautmann M. Cost effectiveness of fluticasone propionate and budesonide in patients with moderate asthma. Clin Drug Invest 1998; 16: 117-123 .
28. Venables TL, McConchie S, Follows RMA. A comparison of the cost-effectiveness of budesonide and fluticasone dry-powder devices in the management of adult asthma. Br J Med Econ 1996; 10: 315-323.